Research programme: ERX 1000 analogues - ERX Pharmaceuticals
Alternative Names: Research programme: Next generation candidates - ERX PharmaceuticalsLatest Information Update: 28 Sep 2025
At a glance
- Originator ERX Pharmaceuticals
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for preclinical development in Obesity in USA
- 31 Aug 2021 ERX parmaceuticals plans a Phase I trial for Obesity in US in 2021 (ERX Pharmaceuticals pipeline, August 2021)
- 27 Aug 2021 Preclinical trials in Obesity in USA (ERX Pharmaceuticals pipeline, August 2021)